Dengue VLP Protein (Serotype 3)

• Description:

  Dengue VLP Protein (Serotype 3)_x000D_ Catalog number: B2012149_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 100 µg_x000D_ Molecular Weight or Concentration: 200-800 µg/mL_x000D_ Supplied as: Solution_x000D_ Applications: molecular tool for various biochemical applications_x000D_ Storage: -20 °C_x000D_ Keywords: DENV protein, Dengue protein, Dengue virus-like particles protein, Dengue virus like particles protein, Dengue virus-like particles serotype 3, Dengue VLP protein subtype 3_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Lin HH, Yip BS, Huang LM, Wu SC. Zika virus structural biology and progress in vaccine development Biotechnol Adv. 2018 Jan-Feb;36(1):47-53._x000D_ 2: Imagawa T, Ito M, Matsuda M, Nakashima K, Tokunaga Y, Ohta I, Li TC, Suzuki R, Suzuki T. Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate Sci Rep. 2021 Sep 2;11(1):17542._x000D_ 3: Galula JU, Salem GM, Destura RV, Remenyi R, Chao DY. Comparable Accuracies of Nonstructural Protein 1- and Envelope Protein-Based Enzyme-Linked Immunosorbent Assays in Detecting Anti-Dengue Immunoglobulin G Antibodies Diagnostics (Basel). 2021 Apr 21;11(5):741._x000D_ 4: Boigard H, Cimica V, Galarza JM. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature Vaccine. 2018 Nov 29;36(50):7728-7736._x000D_ 5: Cuevas-Juárez E, Pando-Robles V, Palomares LA. Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives Vaccine. 2021 Nov 26;39(48):6990-7000._x000D_ 6: Shang W, Liu J, Yang J, Hu Z, Rao X. Dengue virus-like particles: construction and application Appl Microbiol Biotechnol. 2012 Apr;94(1):39-46._x000D_ 7: Cimica V, Williams S, Adams-Fish D, McMahon C, Narayanan A, Rashid S, Stedman TT. Zika Virus-Like Particle (VLP) vaccine displaying Envelope (E) protein CD loop antigen elicits protective and specific immune response in a murine model Biochem Biophys Res Commun. 2020 Aug 27;529(3):805-811._x000D_ 8: Warner NL, Frietze KM. Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1 Vaccines (Basel). 2021 Jul 2;9(7):726._x000D_ 9: Hsieh SC, Tsai WY, Wang WK. The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum J Virol. 2010 May;84(9):4782-97._x000D_ 10: Khetarpal N, Poddar A, Nemani SK, Dhar N, Patil A, Negi P, Perween A, Viswanathan R, Lünsdorf H, Tyagi P, Raut R, Arora U, Jain SK, Rinas U, Swaminathan S, Khanna N. Dengue-specific subviral nanoparticles: design, creation and characterization J Nanobiotechnology. 2013 May 25;11:15. _x000D_ _x000D_ Products Related to Dengue VLP Protein (Serotype 3) can be found at Proteins

• Short Description:

  Catalog Number: B2012149 (100 µg)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5